|
1
|
Ferlay J, Autier P, Boniol M, Heanue M,
Colombet M and Boyle P: Estimates of the cancer incidence and
mortality un Europe in 2006. Ann Oncol. 18:581–592. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Sáenz S, Conejo-Mir J and Cayuela A:
Melanoma epidemiology in Spain. Actas Dermosifiliogr. 96:411–418.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Balch CM, Gershenwald JE, Soong SJ,
Thompson JF, Atkins MB, Byrd DR, Buzaid AC, Cochran AJ, Coit DG,
Ding S, et al: Final version of 2009 AJCC melanoma staging and
classification. J Clin Oncol. 27:6199–6206. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Slingluff CI Jr, Flaherty K, Rosenberg SA,
et al: Cutaneous melanomaDeVita VT Jr, Lawrence TS and Rosenberg
SA: Cancer. Principles and Practice of Oncology. 9th edition.
Philadelphia, Pa: Lippincott Williams & Wilkins; pp. 1643–1691.
2011
|
|
5
|
Balch CM, Soong SJ, Gershenwald JE,
Thompson JF, Reintgen DS, Cascinelli N, Urist M, McMasters KM, Ross
MI, Kirkwood JM, et al: Prognostic factors analysis of 17,600
melanoma patients: Validation of the American joint committe on
cancer melanoma staging system. J Clin Oncol. 19:3622–3634.
2001.PubMed/NCBI
|
|
6
|
Balch CM, Gershenwald JE, Soong SJ,
Thompson JF, Atkins MB, Byrd DR, Buzaid AC, Cochran AJ, Coit DG,
Ding S, et al: Final version of 2009 AJCC melanoma staging and
classification. J Clin Oncol. 27:6199–6206. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Balch CM, Soong SJ, Ross MI, Urist MM,
Karakousis CP, Temple WJ, Mihm MC, Barnhill RL, Jewell WR, Wanebo
HJ and Harrison R: Long-term results of a multi-institutional
randomized trial comparing prognostic factors and surgical results
for intermediate thickness melanomas (1.0 to 4.0 mm). Intergroup
Melanoma Surgical Trial. Ann Surg Oncol. 7:87–97. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Manola J, Atkins M, Ibrahim J and Kirkwood
J: Prognostic factors in metastatic melanoma: A pooled analysis of
eastern cooperative oncology group trials. J Clin Oncol.
18:3782–3793. 2000.PubMed/NCBI
|
|
9
|
Berrocal A, Arance A, Espinosa E, Castaño
AG, Cao MG, Larriba JL, Martín JA, Márquez I, Soria A and Algarra
SM: SEOM guidelines for the management of malignant melanoma 2015.
Clin Transl Oncol. 17:1030–1035. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Kirwood JM, Strawderman MH, Ernstoff MS,
Smith TJ, Borden EC and Blum RH: Interferon alfa-2b adjuvant
therapy of high-risk resected cutaneous melanoma: The Eastern
Cooperative Oncology Group Trial EST 1684. J Clin Oncol. 14:7–17.
1996.PubMed/NCBI
|
|
11
|
Kirwood JM, Ibrahim JG, Sondak VK,
Richards J, Flaherty LE, Ernstoff MS, Smith TJ, Rao U, Steele M and
Blum RH: High-and low-dose interferon alfa-2b in high risk
melanoma: First analysis of intergroup trial E1690/S9111/C9190. J
Clin Oncol. 18:2444–2458. 2000.PubMed/NCBI
|
|
12
|
Eggermont AM, Suciu S, Santinami M,
Testori A, Kruit WH, Marsden J, Punt CJ, Salès F, Gore M, Mackie R,
et al: Adjuvant therapy with pegylated interferón alfa-2b versus
observation alone in resected stage III melanoma: Final results of
EORCT 18991, a randomised phase III trial. Lancet. 372:117–126.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Burmeister BH, Henderson MA, Ainslie J,
Fisher R, Di Iulio J, Smithers BM, Hong A, Shannon K, Scolyer RA,
Carruthers S, et al: Adjuvant radiotherapy versus observation alone
for patients at risk of lymph-node field relapse after therapeutic
lymphadenectomy for melanoma: A randomised trial. Lancet Oncol.
13:589–597. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Chapman PB, Einhorn LH, Meyers ML, Saxman
S, Destro AN, Panageas KS, Begg CB, Agarwala SS, Schuchter LM,
Ernstoff MS, et al: Phase III multicenter randomized trial of the
Dartmouth regimen versus dacarbazine in patients with metastatic
melanoma. J Clin Oncol. 17:2745–2751. 1999.PubMed/NCBI
|
|
15
|
Middleton MR, Grob JJ, Aaronson N,
Fierlbeck G, Tilgen W, Seiter S, Gore M, Aamdal S, Cebon J, Coates
A, et al: Randomized phase III study of temozolomide versus
dacarbazine in the treatment of patients with advanced metastatic
malignant melanoma. J Clin Oncol. 18:158–166. 2000.PubMed/NCBI
|
|
16
|
Hodi FS, O'Day SJ, McDermott DF, Weber RW,
Sosman JA, Haanen JB, Gonzalez R, Robert C, Schadendorf D, Hassel
JC, et al: Improved survival with ipilimumab in patients with
metastatic melanoma. N Engl J Med. 363:711–723. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Robert C, Thomas L, Bondarenko I, O'Day S,
Weber J, Garbe C, Lebbe C, Baurain JF, Testori A, Grob JJ, et al:
Ipilimumab plus dacarbazine for previously untreated metastatic
melanoma. N Engl J Med. 364:2517–2526. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Davies H, Bignell GR, Cox C, Stephens P,
Edkins S, Clegg S, Teague J, Woffendin H, Garnett MJ, Bottomley W,
et al: Mutations of the BRAF gene in human cancer. Nature.
417:949–954. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Curtin JA, Fridlyand J, Kageshita T, Patel
HN, Busam KJ, Kutzner H, Cho KH, Aiba S, Bröcker EB, LeBoit PE, et
al: Distinct sets of genetic alterations in melanoma. N Engl J Med.
353:2135–2147. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Chapman PB, Hauschild A, Robert C, Haanen
JB, Ascierto P, Larkin J, Dummer R, Garbe C, Testori A, Maio M, et
al: Improved survival with vemurafenib in melanoma with BRAF V600E
mutation. N Engl J Med. 364:2507–2516. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Hauschild A, Grob JJ, Demidov LV, Jouary
T, Gutzmer R, Millward M, Rutkowski P, Blank CU, Miller WH Jr,
Kaempgen E, et al: Dabrafenib in BRAF-mutated metastatic melanoma:
A multicentre, open-label, phase 3 randomised controlled trial.
Lancet. 380:358–365. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Rizos H, Menzies AM, Pupo GM, Carlino MS,
Fung C, Hyman J, Haydu LE, Mijatov B, Becker TM, Boyd SC, et al:
BRAF inhibitor resistance mechanisms in metastatic melanoma:
Spectrum and clinical impact. Clin Cancer Res. 20:1965–1977. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
VanAllen EM, Wagle N, Sucker A, Treacy DJ,
Johannessen CM, Goetz EM, Place CS, TaylorWeiner A, Whittaker S,
Kryukov GV, et al: The genetic landscape of clinical resistance to
RAF inhibition in metastatic melanoma. Cancer Discov. 4:94–109.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Shi H, Hugo W, Kong X, Hong A, Koya RC,
Moriceau G, Chodon T, Guo R, Johnson DB, Dahlman KB, et al:
Acquired resistance and clonal evolution in melanoma during BRAF
inhibitor therapy. Cancer Discov. 4:80–93. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Flaherty KT, Robert C, Hersey P, Nathan P,
Garbe C, Milhem M, Demidov LV, Hassel JC, Rutkowski P, Mohr P, et
al: Improved survival with MEK inhibition in BRAF-mutated melanoma.
N Engl J Med. 367:107–114. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Robert C, Karaszewska B, Schachter J,
Rutkowski P, Mackiewicz A, Stroiakovski D, Lichinitser M, Dummer R,
Grange F, Mortier L, et al: Improved overall survival in melanoma
with combined dabrafenib and trametinib. N Engl J Med. 372:30–39.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Dueck AC, Mendoza TR, Mitchell SA, Reeve
BB, Castro KM, Rogak LJ, Atkinson TM, Bennett AV, Denicoff AM,
O'Mara AM, et al: Validity and Reliability of the US National
Cancer Institute's Patient-Reported Outcomes Version of the Common
Terminology Criteria for Adverse Events (PRO-CTCAE). JAMA Oncol.
1:1051–1059. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Eisenhauer EA, Therasse P, Bogaerts J,
Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S,
Mooney M, et al: New response evaluation criteria in solid tumours:
Revised RECIST guideline (version 1.1). Eur J Cancer. 45:228–247.
2009. View Article : Google Scholar : PubMed/NCBI
|
